Resveratrol induces catalytic bioscavenger paraoxonase 1 expression and protects against chemical warfare nerve agent toxicity in human cell lines

Journal of Cellular Biochemistry

Volumn 103, Issue 5, 2008, Pages 1524-1535

  Curtin, Bryan F ^a   Seetharam, Karthik I ^a   Dhoieam, Pilin ^a   Gordon, Richard K ^a   Doctor, Bhupendra P ^a   Nambiar, Madhusoodana P ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Nerve agents; Neuroprotection; Organophosphates; Paraoxonase gene expression; Transcriptional inducers

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHEMICAL WARFARE AGENT; RESVERATROL; SARIN; SOMAN;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYLDIALKYLPHOSPHATASE; BUTYRYLCHOLINESTERASE; CELL LINE; CHEMICAL WARFARE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HUMANS; MICE; SARIN; SOMAN; STILBENES;

ANIMALIA; RICE STRIPE VIRUS;

EID: 41749119650     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21543     Document Type: Article

References (62)

1. Adkins S, Gan KN, Mody M, La Du BN. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598-608.
2. Aviram M. 1999. Cholesterol oxidation, macrophage foam cells and atherosclerosis: Importance of antioxidants and paraoxonase. Harefuah 136:620-626.
3. Bajgar J, Sevelova L, Krejcova G, Fusek J, Vachek J, Kassa J, Herink J, De Jong LP, Benschop HP. 2004a. Biochemical and behavioral effects of soman vapors in low concentrations. Inhal Toxicol 16:497-507.
4. Bajgar J, Sevelova L, Krejcova G, Fusek J, Vachek J, Kassa J, Herink J, De Jong LP, Benschop HP. 2004b. Biochemical and behavioral effects of soman vapors in low concentrations. Inhal Toxicol 16:497-507.
5. Boemi M, Sirolla C, Testa R, Cenerelli S, Fumelli P, James RW. 2004. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabet Med 21:423-427.
6. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA. 1998. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 139:131-136.
7. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13:357-364.
8. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. 1999a. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 119-120:429-438.
9. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. 1999b. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 119-120:429-438.
10. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. 1999c. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 119-120:429-438.
11. Costa LG, Cole TB, Furlong CE. 2003a. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J Toxicol Clin Toxicol 41:37-45.
12. Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. 2003b. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 8:1-12.
13. Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. 2003c. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 8:1-12.
14. Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. 2003d. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 8:1-12.
15. Costa LG, Cole TB, Vitalone A, Furlong CE. 2005a. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352:37-47.
16. Costa LG, Vitalone A, Cole TB, Furlong CE. 2005b. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550.
17. Curtin BF, Tetz LM, Compton JR, Doctor BP, Gordon RK, Nambiar MP. 2005. Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure. J Cell Biochem 96:839-849.
18. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. 1996a. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
19. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. 1996b. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
20. Doctor BP, Saxena A. 2005. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 157-158:167-171.
21. Doctor BP, Raveh L, Wolfe AD, Maxwell DM, Ashani Y. 1991. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci Biobehav Rev 15:123-128.
22. Ehrich M, Jortner BS, Padilla S. 1995. Comparison of the relative inhibition of acetylcholinesterase and neuropathy target esterase in rats and hens given cholinesterase inhibitors. Fundam Appl Toxicol 24:94-101.
23. Fu AL, Wang YX, Sun MJ. 2005a. Naked DNA prevents soman intoxication. Biochem Biophys Res Commun 328:901-905.
24. Fu AL, Wang YX, Sun MJ. 2005b. Naked DNA prevents soman intoxication. Biochem Biophys Res Commun 328:901-905.
25. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. 1989. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 180:242-247.
26. Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, Costa LG. 2000. Genetic and temporal determinants of pesticide sensitivity: Role of paraoxonase (PON1). Neurotoxicology 21:91-100.
27. Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. 2005. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol 19:182-183.
28. Geldmacher-von Mallinckrodt M, Diepgen TL, Enders PW. 1984. Interethnic differences of human serum paraoxonase activity-relevance for the detoxification of organophosphorous compounds. Arch Belg (Suppl):243-251.
29. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP. 2005. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact
30. Gouedard C, Koum-Besson N, Barouki R, Morel Y. 2003. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 63:945-956.
31. Gouedard C, Barouki R, Morel Y. 2004a. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 24:5209-5222.
32. Gouedard C, Barouki R, Morel Y. 2004b. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 24:2378-2383.
33. Gouedard C, Barouki R, Morel Y. 2004c. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 24:2378-2383.
34. Gouedard C, Barouki R, Morel Y. 2004d. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 24:2378-2383.
35. Haley RW. 2003. Gulf war syndrome: Narrowing the possibilities. Lancet Neurol 2:272-273.
36. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. 1991a. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 30:10141-10149.
37. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. 1991b. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 30:10141-10149.
38. Kropp T, Richardson R. 2003a. Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase. J Toxicol Environ Health A 66:1145-1157.
39. Kropp T, Richardson R. 2003b. Relative inhibitory potencies of chlorpyrifos oxon, chlorpyrifos methyl oxon, and mipafox for acetylcholinesterase versus neuropathy target esterase. J Toxicol Environ Health A 66:1145-1157.
40. La Du BN. 1996. Structural and functional diversity of paraoxonases. Nat. Med 2:1186-1187.
41. Li WF, Costa LG, Furlong CE. 1993. Serum paraoxonase status: A major factor in determining resistance to organophosphates. J Toxicol Environ Health 40:337-346.
42. Li WF, Furlong CE, Costa LG. 1995a. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 76:219-226.
43. Li WF, Furlong CE, Costa LG. 1995b. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 76:219-226.
44. Lum KT, Huebner HJ, Li Y, Phillips TD, Raushel FM. 2003. Organophosphate nerve agent toxicity in Hydra attenuata. Chem Res Toxicol 16:953-957.
45. Mackness MI, Walker CH. 1988a. Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. Biochem J 250:539-545.
46. Mackness MI, Walker CH. 1988b. Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. Biochem J 250:539-545.
47. Mackness B, Durrington PN, Mackness MI. 1998. Human serum paraoxonase. Gen Pharmacol 31:329-336.
48. Magnotti RA Jr, Eberly JP, Quarm DE, McConnell RS. 1987a. Measurement of acetylcholinesterase in erythrocytes in the field. Clin Chem 33:1731-1735.
49. Magnotti RA, Jr., Eberly JP, Quarm DE, McConnell RS. 1987b. Measurement of acetylcholinesterase in erythrocytes in the field. Clin Chem 33:1731-1735.
50. Magnotti RA, Jr., Eberly JP, Quarm DE, McConnell RS. 1987c. Measurement of acetylcholinesterase in erythrocytes in the field. Clin Chem 33:1731-1735.
51. Mallinckrodt M, Hommel G, Dumbach J. 1979. On the genetics of the human serum paraoxonase (EC 3.1.1.2). Hum Genet 50:313-326.
52. Maxwell DM, Brecht KM, O'Neill BL. 1987. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Lett 39:35-42.
53. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
54. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. 1983. Plasma paraoxonase polymorphism: A new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 35:393-408.
55. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996a. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
56. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996b. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
57. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996c. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
58. Raveh L, Ashani Y, Levy D, De La HD, Wolfe AD, Doctor BP. 1989. Acetylcholinesterase prophylaxis against organophosphate poisoning. Quantitative correlation between protection and blood-enzyme level in mice. Biochem Pharmacol 38:529-534.
59. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287.
60. Simeon V, Pavkovic E. 1993. Heat inactivation of paraoxonase and arylesterase activities in human and rabbit serum. Chem Biol Interact 87:103-107.
61. Worth J. 2002. Paraoxonase polymorphisms and organophosphates. Lancet 360:802-803.
62. Yamasaki Y, Sakamoto K, Watada H, Kajimoto Y, Hori M. 1997. The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. Hum Genet 101:67-68.